Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
HAT
MCID: HPR003
MIFTS: 49

Heparin-Induced Thrombocytopenia (HAT)

Categories: Blood diseases, Immune diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Heparin-Induced Thrombocytopenia

About this section

MalaCards integrated aliases for Heparin-Induced Thrombocytopenia:

Name: Heparin-Induced Thrombocytopenia 53 59 73
Hit 53 59
Heparin-Induced Thrombocytopenia Type 2 59
Heparin-Associated Thrombocytopenia 59
Hat 59

Characteristics:

Orphanet epidemiological data:

59
heparin-induced thrombocytopenia
Inheritance: Not applicable; Age of onset: All ages;

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Blood diseases Immune diseases
See all MalaCards categories (disease lists)
ICD10: 34
Orphanet: 59  
Rare haematological diseases


External Ids:

Orphanet 59 ORPHA3325
UMLS via Orphanet 74 C0272285
ICD10 via Orphanet 34 D69.5
UMLS 73 C0272285
Sources

Summaries for Heparin-Induced Thrombocytopenia

About this section
NIH Rare Diseases : 53 Heparin-induced thrombocytopenia (HIT) is an adverse reaction to the drug heparin resulting in an abnormally low amount of platelets (thrombocytopenia). HIT is usually an immune response which typically occurs 4-10 days after exposure to heparin; it can lead to serious complications and be life-threatening. This condition occurs in up to 5% of those who are exposed to heparin. Characteristic signs of HIT are a drop in platelet count of  greater than 50% and/or the formation of new blood clots during heparin therapy.  The first step of treatment is to discontinue and avoid all heparin products immediately. Often, affected individuals require another medicine to prevent blood clotting (anticoagulants).

MalaCards based summary : Heparin-Induced Thrombocytopenia, also known as hit, is related to thrombosis and pulmonary embolism. An important gene associated with Heparin-Induced Thrombocytopenia is F3 (Coagulation Factor III, Tissue Factor), and among its related pathways/superpathways are Collagen chain trimerization and Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers. The drugs Heparin and Dalteparin have been mentioned in the context of this disorder. Affiliated tissues include testes, liver and heart, and related phenotypes are hematopoietic system and immune system

Wikipedia : 76 Heparin-induced thrombocytopenia (HIT) is the development of thrombocytopenia (a low platelet count),... more...

Sources

Related Diseases for Heparin-Induced Thrombocytopenia

About this section

Diseases related to Heparin-Induced Thrombocytopenia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 155)
# Related Disease Score Top Affiliating Genes
1 thrombosis 31.2 F10 F3 SERPINC1
2 pulmonary embolism 30.6 F10 F3 SERPINC1
3 catastrophic antiphospholipid syndrome 30.4 CD40LG F3
4 budd-chiari syndrome 30.4 F3 SERPINC1
5 thrombophilia due to thrombin defect 30.3 F10 F3 SERPINC1
6 coronary thrombosis 30.3 F3 SERPINC1
7 antiphospholipid syndrome 30.2 CD40LG F10 F3 SERPINC1
8 endocarditis 30.1 FCGR2A SERPINC1
9 sagittal sinus thrombosis 30.1 F3 SERPINC1
10 autoimmune disease 30.0 CD40LG CD79A FCGR2A
11 disseminated intravascular coagulation 30.0 F3 SERPINC1
12 purpura 30.0 CD79A F3 SERPINC1
13 marantic endocarditis 29.9 F3 SERPINC1
14 myocardial infarction 29.9 CD40LG F10 F3 SERPINC1
15 intracranial thrombosis 29.9 F3 SERPINC1
16 protein s deficiency 29.8 F3 SERPINC1
17 systemic lupus erythematosus 29.8 CD40LG CD79A F3 FCGR2A
18 thrombocytosis 29.7 F3 SERPINC1
19 thrombocytopenia 11.5
20 essential thrombocythemia 10.3
21 paroxysmal nocturnal hemoglobinuria 10.3
22 hemoglobinuria 10.3
23 bilateral massive adrenal hemorrhage 10.3
24 polycythemia vera 10.2
25 acute myocardial infarction 10.2
26 polycythemia 10.2
27 transient global amnesia 10.2
28 ischemia 10.2
29 myocarditis 10.2
30 lupus erythematosus 10.2
31 giant cell myocarditis 10.2
32 acquired hemophilia 10.1 F10 F3
33 carotid artery thrombosis 10.1 F10 F3
34 c1q nephropathy 10.1 CD40LG CD79A
35 immunoglobulin g deficiency 10.1 CD40LG CD79A
36 cryofibrinogenemia 10.1 CD40LG CD79A
37 immunoglobulin a deficiency 1 10.1 CD40LG CD79A
38 sporotrichosis 10.1 CD40LG CD79A
39 congenital syphilis 10.1 CD40LG CD79A
40 syphilis 10.1 CD40LG CD79A
41 secondary syphilis 10.1 CD40LG CD79A
42 immunodeficiency-centromeric instability-facial anomalies syndrome 1 10.1 CD40LG CD79A
43 ocular toxoplasmosis 10.1 CD40LG CD79A
44 toxoplasmosis 10.1 CD40LG CD79A
45 persistent generalized lymphadenopathy 10.1 CD40LG CD79A
46 immunodeficiency with hyper-igm, type 1 10.1 CD40LG CD79A
47 congenital toxoplasmosis 10.1 CD40LG CD79A
48 immunoglobulin alpha deficiency 10.1 CD40LG CD79A
49 cryptosporidiosis 10.1 CD40LG CD79A
50 hemophilia a 10.1 F10 F3

Graphical network of the top 20 diseases related to Heparin-Induced Thrombocytopenia:



Diseases related to Heparin-Induced Thrombocytopenia
Sources

Symptoms & Phenotypes for Heparin-Induced Thrombocytopenia

About this section

MGI Mouse Phenotypes related to Heparin-Induced Thrombocytopenia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.35 CD40LG CD79A F3 FCGR2A SERPINC1
2 immune system MP:0005387 9.02 CD40LG CD79A F3 FCGR2A SERPINC1
Sources

Drugs & Therapeutics for Heparin-Induced Thrombocytopenia

About this section

Drugs for Heparin-Induced Thrombocytopenia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 66)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 9005-49-6 772 46507594
2
Dalteparin Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 9005-49-6
3 Certoparin Approved, Investigational Phase 4
4
Enoxaparin Approved Phase 4,Phase 2,Phase 3 9005-49-6 772
5
Tinzaparin Approved Phase 4 9005-49-6, 9041-08-1 25244225
6
Fondaparinux Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 104993-28-4
7
Bivalirudin Approved, Investigational Phase 4,Phase 3,Phase 1 128270-60-0 16129704
8
Argatroban Approved, Investigational Phase 4,Phase 3,Phase 2 74863-84-6 152951
9
Nadroparin Approved, Investigational Phase 4
10
Desirudin Approved Phase 4,Phase 2,Phase 3 120993-53-5
11
Thrombin Approved, Investigational Phase 4,Phase 3,Phase 2
12
Lepirudin Approved Phase 4 120993-53-5, 138068-37-8 16132441
13
Warfarin Approved Phase 4,Phase 3,Phase 2,Not Applicable 81-81-2 6691 54678486
14
Serine Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 56-45-1 5951
15 Calcium, Dietary Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16 Immunoglobulins Phase 4,Phase 3,Phase 1
17 Anticoagulants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18 Antibodies Phase 4,Phase 3,Phase 1
19 calcium heparin Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 Fibrinolytic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
21 Heparin, Low-Molecular-Weight Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
22
protease inhibitors Phase 4,Phase 3,Phase 2,Phase 1
23 Antithrombin III Phase 4,Phase 3,Phase 2,Phase 1
24 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
25 Antithrombins Phase 4,Phase 3,Phase 2,Phase 1
26 Serine Proteinase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
27 Immunologic Factors Phase 4,Phase 1
28 PENTA Phase 4,Phase 3,Phase 2,Phase 1
29 Factor Xa Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
30 Hirudins Phase 4,Phase 3,Phase 2,Phase 1
31 Platelet Aggregation Inhibitors Phase 4,Phase 3,Phase 2
32 Thromboplastin Phase 4,Phase 3,Phase 2
33 Liver Extracts Phase 4
34 Platelet Factor 4 Phase 4,Not Applicable
35
Bilirubin Phase 4 635-65-4 5280352
36 Coagulants Phase 4
37
Benzocaine Approved, Investigational Phase 3 94-09-7, 1994-09-7 2337
38 tannic acid Approved Phase 3
39
Rivaroxaban Approved Phase 3,Phase 2 366789-02-8
40
Ethanol Approved Phase 3 64-17-5 702
41 Kava Approved, Investigational, Nutraceutical Phase 2, Phase 3 9000-38-8
42
Creatine Approved, Investigational, Nutraceutical Phase 2, Phase 3 57-00-1 586
43
Citric Acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
44 Citrate Phase 3
45 Anti-Infective Agents Phase 3
46 Central Nervous System Depressants Phase 3
47 Pharmaceutical Solutions Phase 3
48 Anti-Infective Agents, Local Phase 3
49
Apixaban Approved Phase 2 503612-47-3 10182969
50
Carboplatin Approved Phase 2 41575-94-4 10339178 38904 498142

Interventional clinical trials:

(show top 50) (show all 78)
# Name Status NCT ID Phase Drugs
1 The HIT-TRAP Trial Unknown status NCT00196417 Phase 4 Standard heparin (UFH) versus certoparin (LMWH)
2 Efficacy and Safety of Heparin-coated Surface-treated Polyacrylonitrile Membrane Hemofilter in Critical Ill CRRT Patients Unknown status NCT02355873 Phase 4
3 Impact of Heparin on the Need for Mechanical Ventilation in Neonates Unknown status NCT00196469 Phase 4 heparin
4 Bivalirudin PCI Registry in Heparin Induced Thrombocytopenia/Heparin Induced Thrombocytopenia and Thrombosis Syndrome (HIT/HITTS) Patients Completed NCT00759083 Phase 4 bivalirudin
5 Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin Completed NCT00039858 Phase 4 Argatroban
6 Venous Thromboembolic Prophylaxis After Trauma: Three Times a Day Unfractionated Heparin Versus Twice a Day Enoxaparin Completed NCT01729559 Phase 4 5000 Units unfractionated Heparin Q 8 hr;30mg enoxaparin Q12 hr
7 Nadroparin for the Initial Treatment of Pulmonary Thromboembolism Completed NCT00796692 Phase 4 Nadroparin;Unfractionated heparin(UFH)
8 Study to Evaluate the Mortality Reduction of Enoxaparin in Hospitalized Acutely Ill Medical Receiving Enoxaparin Completed NCT00622648 Phase 4 Enoxaparin;Placebo
9 EXCLAIM:Extended Prophylaxis for Venous ThromboEmbolism (VTE) in Acutely Ill Medical Patients With Prolonged Immobilization Completed NCT00077753 Phase 4 enoxaparin sodium
10 Safety Study of Desirudin, an Anticoagulant for the Prophylaxis of Thrombosis Completed NCT00913133 Phase 4 Desirudin
11 Efficacy of Low Molecular Weight Heparin in Superficial Vein Thrombosis Completed NCT01245998 Phase 4 Dalteparin;Dalteparin
12 Maintaining Patency in Implanted Port Catheters Recruiting NCT02354118 Phase 4
13 Comparison of Low and Intermediate Dose Low-molecular-weight Heparin to Prevent Recurrent Venous Thromboembolism in Pregnancy Recruiting NCT01828697 Phase 4 Low dose nadroparin;Intermediate dose nadroparin;Low dose enoxaparin;Intermediate dose enoxaparin;Low dose dalteparin;Intermediate dose dalteparin;Fixed low dose tinzaparin;Intermediate dose tinzaparin
14 A Comparative Sudy Comparing Argatroban® IV vs Desirudin SC for Suspected HIT With or Without Thrombosis Syndrome Terminated NCT00787332 Phase 4 Desirudin or Argatroban®
15 Argatroban Versus Lepirudin in Critically Ill Patients Terminated NCT00798525 Phase 4 Argatroban;Lepirudin
16 Significance of Antibodies to Heparin/Platelet Factor 4 Complex in Vein Graft Patency and Potential Role of Argatroban for Prevention of Vein Graft Occlusion Terminated NCT01246011 Phase 4 Argatroban and warfarin
17 Maintaining Patency in BioFlo Implanted Port Catheters With Saline Only Flushes Terminated NCT02923830 Phase 4 Saline-only catheter flush
18 Fondaparinux in Patients With Acute Heparin-Induced Thrombocytopenia (HIT) Withdrawn NCT00603824 Phase 4 fondaparinux;argatroban or lepirudin
19 Fondaparinux to Prevent Thrombotic Complications and Graft Failure in Patients Undergoing Coronary Artery Bypass Graft Surgery: The Fonda CABG Study Unknown status NCT00474591 Phase 3 Fondaparinux
20 Efficacy and Safety Study of Argatroban to Treat Heparin-Induced Thrombocytopenia Completed NCT00198588 Phase 3 argatroban
21 Anticoagulant Therapy With Bivalirudin in the Performance of Percutaneous Coronary Intervention in Patients With Heparin-Induced Thrombocytopenia (AT BAT, First Inning) Completed NCT00043940 Phase 3 bivalirudin
22 Angiomax in Patients With HIT/HITTS Type II Undergoing CPB Completed NCT00079508 Phase 3 Angiomax (bivalirudin)
23 Angiomax in Patients With HIT/HITTS Type II Undergoing Off-Pump Coronary Artery Bypass Grafting (CABG) (CHOOSE) Completed NCT00073580 Phase 3 Angiomax (bivalirudin) anticoagulant
24 Heparin 100U/L for Prevention of PVC Complications Completed NCT01131754 Phase 3
25 PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT) Completed NCT00182143 Phase 3 LMWH (Fragmin, dalteparin);Unfractionated Heparin
26 The Use of Fondaparinux in Preventing Thromboembolism in High Risk Trauma Patients Completed NCT00531843 Phase 2, Phase 3 fondaparinux sodium
27 PROSPER: PostpaRtum PrOphylaxiS for PE Randomized Control Trial Pilot Completed NCT01274637 Phase 3 Dalteparin Sodium
28 Study Comparing Desirudin With Heparin to Prevent Vein Clots After Heart and Lung Surgery Completed NCT00329433 Phase 2, Phase 3 Desirudin (Iprivask™);Heparin
29 A Safety and Efficacy Study of BCD-080 Compared to Clexan for Deep Vein Thrombosis Prophylaxis at Orthopedic Surgeries Completed NCT02368314 Phase 3 Sodium Enoxaparine
30 Multi-Center Single Arm Trial to Determine The Effectiveness of Warfarin Therapy Duration For Heparin-Induced Thrombocytopenia (HIT) Recruiting NCT03147638 Phase 3 Warfarin, NOAC
31 An Open-Label, Randomised, Active Controlled, Multi-Centre Phase 3 Study to Evaluate the Safety and Efficacy of Danaparoid vs Argatroban in Treatment of Subjects With Acute HIT Not yet recruiting NCT03809481 Phase 3 Danaparoid Sodium;Argatroban
32 Evaluation of the Efficacy of an inTerdialytic "Ethanol 40% v/v - enoxapaRin 1000 U/mL" Lock solutioN to Prevent Tunnelled Catheter Infections in Chronic Hemodialysis Patients Not yet recruiting NCT03083184 Phase 3 Ethanol;enoxaparin
33 Impact on Morbidity and Mortality of Prophylactic Dosing of Low Molecular Heparin in Child-Pugh B Cirrhotic Patients Suspended NCT02271295 Phase 3 Enoxaparine
34 Rivaroxaban for Treatment of Patients With Suspected or Confirmed Heparin-Induced Thrombocytopenia Terminated NCT01598168 Phase 3 Rivaroxaban
35 Trial of Nebulized Heparin Versus Placebo for Inhalation Trauma Terminated NCT01773083 Phase 3 unfractionated heparin;placebo
36 Clinical Management of Argatroban in Patients With Heparin Induced Thrombocytopenia Type II Completed NCT00861692 Phase 2 argatroban
37 ODiXahip - a Phase IIa Dose Escalating Proof of Principle Trial Completed NCT00839826 Phase 2 Rivaroxaban (BAY59-7939);Enoxaparin
38 Extended Low-Molecular Weight Heparin VTE Prophylaxis in Thoracic Surgery Completed NCT02334007 Phase 1, Phase 2 LMWH: Dalteparin
39 Efficacy and Safety of Apixaban in the Treatment of Heparin Induced Thrombocytopenia (HIT) Recruiting NCT03594045 Phase 2 Apixaban
40 Addition of Enoxaparin to Neoadjuvant Chemoradiation of Esophageal Cancer Recruiting NCT03254511 Phase 2 Enoxaparin Sodium 40 MG/0.2 ML Subcutaneous Injectable;Chemotherapeutic Combinations
41 Aneurysmal Subarachnoid Hemorrhage Trial RandOmizing Heparin Recruiting NCT02501434 Phase 2 Continuous Low-Dose IV Unfractionated Heparin Infusion
42 Heparin Anticoagulation in Septic Shock Recruiting NCT03378466 Phase 2 Unfractionated heparin
43 Catheter-Related Early Thromboprophylaxis With Enoxaparin (CRETE) Trial Recruiting NCT03003390 Phase 2 Enoxaparin
44 Fondaparinux for the Treatment of Heparin-Induced Thrombocytopenia (HIT) Terminated NCT00673439 Phase 2 fondaparinux;warfarin
45 Heparin-Induced Thrombocytopenia Score Card Study Completed NCT00489437 Phase 1
46 Pilot Dose Finding and Pharmacokinetic Study of Fondaparinux in Children With Thrombosis Completed NCT00412464 Phase 1 Fondaparinux
47 Bivalirudin vs Heparin in ECMO Patients Not yet recruiting NCT03707418 Phase 1 Heparin Sodium;Bivalirudin Injection [Angiomax]
48 Validating 4Ts for Heparin Induced Thrombocytopenia (HIT) Unknown status NCT00946400
49 A Study on the Prevalence of Heparin-Induced Thrombocytopenia in Cardiovascular Patients Unknown status NCT00198575
50 Generation of Heparin-induced Thrombocytopenia (HIT)-Antibodies Without Prior Heparin Exposure Unknown status NCT01102790

Search NIH Clinical Center for Heparin-Induced Thrombocytopenia

Sources

Genetic Tests for Heparin-Induced Thrombocytopenia

About this section
Sources

Anatomical Context for Heparin-Induced Thrombocytopenia

About this section

MalaCards organs/tissues related to Heparin-Induced Thrombocytopenia:

41
Testes, Liver, Heart, B Cells, Lung, Skin, Endothelial
Sources

Publications for Heparin-Induced Thrombocytopenia

About this section

Articles related to Heparin-Induced Thrombocytopenia:

(show top 50) (show all 2058)
# Title Authors Year
1
Optimization of a fragment linking hit toward Dengue and Zika virus NS5 methyltransferases inhibitors. ( 30368131 )
2019
2
A Case of Posterior Circulation Ischemic Stroke Caused by Heparin-Induced Thrombocytopenia after Detaining Hepatic Arterial Infusion Catheter. ( 29859863 )
2018
3
Laboratory tests for identification or exclusion of heparin induced thrombocytopenia: HIT or miss? ( 29164662 )
2018
4
High ANTI-PF4/Heparin Antibodies Titer and Thromboses Due to Infection 9 Months After Cessation of Heparin in Hemodialyzed Patient With Heparin-Induced Thrombocytopenia. ( 29856115 )
2018
5
Dynamic intercellular redistribution of HIT antigen modulates heparin-induced thrombocytopenia. ( 29914979 )
2018
6
Heparin-Induced Thrombocytopenia during Obstetric Hospital Admissions. ( 29421832 )
2018
7
Abciximab/Heparin During Acute Heparin-induced Thrombocytopenia: A Word of Caution (Reply). ( 29371038 )
2018
8
Heparin-induced thrombocytopenia and thrombosis during high dose melphalan and autologous stem cell transplantation. ( 29903887 )
2018
9
Left ventricular assist device implantation after plasma exchange for heparin-induced thrombocytopenia. ( 29938391 )
2018
10
Phlegmasia Cerulea Dolens Following Heparin-Induced Thrombocytopenia. ( 29422736 )
2018
11
Heparin-induced thrombocytopenia complicating extracorporeal membrane oxygenation support in pediatric patients: review of the literature and alternative anticoagulants. ( 29788841 )
2018
12
Targeted resequencing of a locus for heparin-induced thrombocytopenia on chromosome 5 identified in a genome-wide association study. ( 29934777 )
2018
13
Heparin-induced thrombocytopenia complicating children after the Fontan procedure: Single-center experience and review of the literature. ( 29181882 )
2018
14
Intravenous Immune Globulin to Prevent Heparin-Induced Thrombocytopenia. ( 29742374 )
2018
15
Association of Heparin-Induced Thrombocytopenia With Bacterial Infection in Trauma Patients. ( 29955756 )
2018
16
HITTING the Diagnosis: Testing for Heparin-Induced Thrombocytopenia in Cancer Patients. ( 29901688 )
2018
17
Abciximab/Heparin During Acute Heparin-Induced Thrombocytopenia: A Word of Caution. ( 29305853 )
2018
18
Delayed-onset heparin-induced thrombocytopenia complicated by arterial and venous thromboses. ( 29314517 )
2018
19
Onset of type 1 diabetes mellitus and heparin-induced thrombocytopenia in a patient with Basedow's disease and idiopathic thrombocytopenic purpura: Novel combination as autoimmune polyglandular syndrome. ( 29905024 )
2018
20
Analysis of big data for heparin-induced thrombocytopenia: valuable information but also some doubts. ( 29703334 )
2018
21
Successful Use of Intravenous Immunoglobulin G to Treat Refractory Heparin-Induced Thrombocytopenia With Thrombosis Complicating Peripheral Blood Stem Cell Harvest. ( 29404376 )
2018
22
Disease burden, complication rates, and health-care costs of heparin-induced thrombocytopenia in the USA: a population-based study. ( 29703336 )
2018
23
A Patient With Remote Heparin-Induced Thrombocytopenia and Antiphospholipid Syndrome Requiring Cardiopulmonary Bypass: Do Current Guidelines Apply? ( 29871549 )
2018
24
Initial and long term impact of a multi-disciplinary task force in the diagnosis and management of heparin-induced thrombocytopenia. ( 29185142 )
2018
25
The Use of Cangrelor and Heparin for Anticoagulation in a Patient Requiring Pulmonary Thromboendarterectomy Surgery with Suspected Heparin-Induced Thrombocytopenia. ( 29853315 )
2018
26
A novel diagnostic algorithm for heparin-induced thrombocytopenia. ( 29756276 )
2018
27
Haemodialysis-related-heparin-induced thrombocytopenia: Case series and literature review. ( 29871769 )
2018
28
Cellular immune responses to platelet factor 4 and heparin complexes in patients with heparin-induced thrombocytopenia. ( 29723924 )
2018
29
Platelet-Activating Antibodies Are Detectable at the Earliest Onset of Heparin-Induced Thrombocytopenia, With Implications for the Operating Characteristics of the Serotonin-Release Assay. ( 29325985 )
2018
30
Incidence of heparin-induced thrombocytopenia in lower-extremity free flap reconstruction correlates with the overall surgical population. ( 29980457 )
2018
31
Plasma exchange to remove heparin-induced thrombocytopenia antibodies and the use of heparin during cardiopulmonary bypass in critically ill cardiac patients. ( 29802082 )
2018
32
Transient Expression of Interleukin-21 in the Second Hit of Acute Pancreatitis May Potentiate Immune Paresis in Severe Acute Pancreatitis. ( 30451792 )
2018
33
RASA-1 somatic "second hit" mutation in capillary malformation-arteriovenous malformation. ( 30368862 )
2018
34
Is There an Association Between Heparin-Induced Thrombocytopenia (HIT) and Autoimmune Disease? ( 29677409 )
2018
35
Double-hit or dual expression of MYC and BCL2 in primary cutaneous large B-cell lymphomas. ( 29581544 )
2018
36
The Multiple Hit Hypothesis for Gulf War Illness: Self-Reported Chemical/Biological Weapons Exposure and Mild Traumatic Brain Injury. ( 30428552 )
2018
37
Chlamydia Spreading from the Genital Tract to the Gastrointestinal Tract - A Two-Hit Hypothesis. ( 29289422 )
2018
38
Long-term Effects of Growth Hormone Replacement Therapy in Childhood-onset Craniopharyngioma: Results of the German Craniopharyngioma Registry (HIT-Endo). ( 30139824 )
2018
39
Radiotherapy for early stage diffuse large B-cell lymphoma with or without double or triple hit genetic alterations. ( 30457458 )
2018
40
Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma. ( 30523716 )
2018
41
Immunohistochemical double hit score enhances NCCN-IPI and is associated with detrimental outcomes in refractory or relapsing patients with diffuse large B cell lymphoma. ( 28875547 )
2018
42
Increased risk of heparin induced thrombocytopenia and thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation. ( 30478722 )
2018
43
Pathogenesis of non-alcoholic fatty liver disease in children and adolescence: From "two hit theory" to "multiple hit model". ( 30038464 )
2018
44
Rifaximin in nonalcoholic fatty liver disease: hit multiple targets with a single shot. ( 30096092 )
2018
45
Testicular double-hit lymphoma in a patient with history of follicular lymphoma with high proliferation index. ( 29674355 )
2018
46
Isolated orbital mass as the primary presentation of a triple-hit lymphoma transformed from a systemic follicular lymphoma. ( 29780927 )
2018
47
Transformation of double-hit follicular lymphoma to plasmablastic lymphoma: a partial role of MYC gene rearrangement. ( 30012920 )
2018
48
Clinicopathological and genomic analysis of double-hit follicular lymphoma: comparison with high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements. ( 28984304 )
2018
49
Heparin-induced thrombocytopenia (HIT): Identification and treatment pathways. ( 30083545 )
2018
50
PIFA PLUSS P4 Assay for Screening of Heparin-Induced Thrombocytopenia. ( 30085261 )
2018
Sources

Variations for Heparin-Induced Thrombocytopenia

About this section
Sources

Expression for Heparin-Induced Thrombocytopenia

About this section
Search GEO for disease gene expression data for Heparin-Induced Thrombocytopenia.
Sources

Pathways for Heparin-Induced Thrombocytopenia

About this section

Pathways related to Heparin-Induced Thrombocytopenia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Collagen chain trimerization 66
Show member pathways
 12.15 F10 F3 SERPINC1
2
Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers 65
11.39 CD79A FCGR2A
3
Formation of Fibrin Clot (Clotting Cascade) 66
Show member pathways
 11.33 F10 F3 SERPINC1
4
Complement and coagulation cascades 1 37
10.94 F10 F3 SERPINC1
5
Primary immunodeficiency 37
10.72 CD40LG CD79A
Sources

GO Terms for Heparin-Induced Thrombocytopenia

About this section

Cellular components related to Heparin-Induced Thrombocytopenia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.43 CD40LG CD79A F10 F3 FCGR2A SERPINC1
2 intrinsic component of external side of plasma membrane GO:0031233 8.62 F10 F3

Biological processes related to Heparin-Induced Thrombocytopenia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 blood coagulation GO:0007596 9.33 F10 F3 SERPINC1
2 B cell differentiation GO:0030183 9.32 CD40LG CD79A
3 B cell proliferation GO:0042100 9.26 CD40LG CD79A
4 blood coagulation, extrinsic pathway GO:0007598 8.96 F10 F3
5 hemostasis GO:0007599 8.8 F10 F3 SERPINC1

Molecular functions related to Heparin-Induced Thrombocytopenia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 phospholipid binding GO:0005543 8.96 F10 F3
2 protease binding GO:0002020 8.62 F3 SERPINC1
Sources

Sources for Heparin-Induced Thrombocytopenia

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....